J P Maffrand Selected Research

niravoline

10/2000

Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J P Maffrand Research Topics

Disease

1	Hyperinsulinism (Hyperinsulinemia) 04/2003
1	Hyperglycemia 04/2003
1	Body Weight (Weight, Body) 04/2003
1	Neoplasms (Cancer) 01/2002
1	Heart Failure 01/2002
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2002
1	Anxiety Disorders (Anxiety Disorder) 01/2002
1	Inappropriate ADH Syndrome (SIADH) 01/2002
1	Atherosclerotic Plaque (Atheroma) 11/2001
1	Nausea 06/2001
1	Vomiting 06/2001
1	Hypertension (High Blood Pressure) 06/2001
1	Diabetes Insipidus 04/2001
1	Ascites 10/2000
1	Fibrosis (Cirrhosis) 10/2000
1	Ocular Hypertension (Glaucoma, Suspect) 06/2000
1	Glaucoma 06/2000

Drug/Important Bio-Agent (IBA)

4	Vasopressins (Vasopressin)IBA 01/2002 - 06/2000
3	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2002 - 06/2000
1	RimonabantIBA 04/2003
1	Blood Proteins (Serum Proteins)IBA 04/2003
1	Messenger RNA (mRNA)IBA 04/2003
1	Nonesterified Fatty Acids (NEFA)IBA 04/2003
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2002
1	1- (5- chloro- 1- ((2,4- dimethoxyphenyl)sulfonyl)- 3- (2- methoxyphenyl)- 2- oxo- 2,3- dihydro- 1H- indol- 3- yl)- 4- hydroxy- N,N- dimethyl- 2- pyrrolidinecarboxamideIBA 01/2002
1	2-oxindole (oxindole)IBA 01/2002
1	CholesterolIBA 11/2001
1	AntiemeticsIBA 06/2001
1	EmeticsIBA 06/2001
1	Cisplatin (Platino)FDA LinkGeneric 06/2001
1	relcovaptanIBA 06/2001
1	satavaptanIBA 04/2001
1	mozavaptanIBA 10/2000
1	niravolineIBA 10/2000
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 10/2000
1	SodiumIBA 10/2000
1	Peptides (Polypeptides)IBA 06/2000

Therapy/Procedure

1	Oral Administration 10/2000